. "ClinicalTrials.gov"@en. "http://clinicaltrials.gov/ct2/show/NCT00478465". . . . . . "Source: Freebase - The World's database". . . "NCT00478465"@en. "Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)"@en. "A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV)"@en. . . . "18"^^. . . "Patients with \"high\" antibody titers against HHV-6 IgG \u2265 640, EBV VCA IgG \u2265 640 and detectable EA Ab at 1:160 or HHV-6 IgG \u2265 320 if EBV VCA IgG \u2265 1280 and has detectable EA Ab at 1:160 (measured by the average of a minimum of two time points obtained during screening at least 3 weeks apart)"@en. "Patient understands and signs the Informed Consent"@en. "Patient agrees to utilize two reliable methods of contraception combined throughout the study period and for 90 days following discontinuation of the Study Drug"@en. "Patients who meet the clinical criteria for the diagnosis of chronic fatigue syndrome as established by the International Chronic Fatigue Syndrome Study Group in 1994"@en. "Patients who had a \"viral onset\" for their CFS"@en. "Patients whose CFS symptoms are not spontaneously improving and have plateau for at least 6 months"@en. "Females of childbearing potential will have a negative pregnancy test at screening"@en. . . . . "Patients with ANC \u22641500 /mm3"@en. "Patients with an active concurrent acute infection"@en. "Patients with abnormal creatinine clearance (\u226460ml/min)"@en. "Patients with any other known chronic viral orbacterial infection for which other treatment(s) is(are) available"@en. "Women in childbearing age considering getting pregnant during the study period"@en. "Patient is a lactating female who will not discontinue nursing prior to study entry"@en. "Patients with other serious co-morbidities which according to the investigator may interfere with the ability of the patient to participate in the study"@en. "Patients with Hb \u2264 10 g/dl"@en. "Patients taking other antiviral medications or who have received antiviral medications within the previous three months"@en. "Previous hypersensitivity or contraindication to Valganciclovir/ganciclovir"@en. "Patients with history of major depression with psychotic or melancholic features before the diagnosis of CFS or who are found to be actively depressed (major depression with psychotic or melancholic features) by the depression instrument used for the study and by a medical evaluation by a psychiatrist"@en. "Patients receiving other experimental therapy"@en. "Patients with platelet count \u2264 100 000/mm3"@en. "Patient requires the use of any prohibited concomitant medications (see Insert on VALCYTE prescribing information)"@en. "Patients who are found to have alternate medical and/or psychiatric causes for their fatigue (see guidelines established by the International Chronic Fatigue Syndrome Study Group in 1994"@en. "Patient is simultaneously participating in another clinical trial"@en. "Patients with history of substance abuse in the past year (excluding nicotine and caffeine) or positive urine test for substance abuse"@en. . . . . . . . .